Adage Capital Partners
AURA icon

Adage Capital Partners’s Aura Biosciences AURA Stock Holding History

Adage Capital Partners’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.9M Sell
4,640,000
-241,125
-5% -$1.73M 0.05% 368
2026
Q1 		$32.7M Hold
4,881,125
– – 0.05% 349
2025
Q4 		$26.6M Hold
4,881,125
– – 0.04% 407
2025
Q3 		$30.2M Hold
4,881,125
– – 0.05% 358
2025
Q2 		$30.6M Hold
4,881,125
– – 0.05% 346
2025
Q1 		$28.6M Hold
4,881,125
– – 0.05% 337
2024
Q4 		$40.1M Hold
4,881,125
– – 0.07% 264
2024
Q3 		$43.5M Sell
4,881,125
-3,875
-0.1% -$33.2K 0.08% 256
2024
Q2 		$36.9M Buy
4,885,000
+420,000
+9% +$3.08M 0.07% 282
2024
Q1 		$35.1M Buy
4,465,000
+240,000
+6% +$1.99M 0.07% 313
2023
Q4 		$37.4M Buy
4,225,000
+1,350,000
+47% +$11.4M 0.08% 258
2023
Q3 		$25.8M Buy
2,875,000
+165,000
+6% +$1.78M 0.06% 325
2023
Q2 		$33.5M Hold
2,710,000
– – 0.07% 271
2023
Q1 		$25.1M Buy
2,710,000
+577,261
+27% +$6M 0.06% 360
2022
Q4 		$22.4M Buy
2,132,739
+681,538
+47% +$8.68M 0.05% 392
2022
Q3 		$26.3M Buy
1,451,201
+174,582
+14% +$2.64M 0.07% 331
2022
Q2 		$18.1M Sell
1,276,619
-20,400
-2% -$338K 0.04% 458
2022
Q1 		$28.5M Buy
1,297,019
+41,539
+3% +$791K 0.05% 351
2021
Q4 		$21.3M Buy
+1,255,480
New +$22.4M 0.04% 443

Other funds holding AURA

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

Adage Capital Partners's AURA Position: Q2 2026 in Review

Adage Capital Partners reduced its Aura Biosciences (AURA) stake by 4.9% in Q2 2026, selling an estimated $1.73M and leaving 4,640,000 shares worth $32.9M. The position accounts for 0.05% of the portfolio, ranked #368.

Adage Capital Partners first reported a position in AURA in Q4 2021 and has held it in 19 quarters since. The position peaked at $43.5M in Q3 2024. 147 funds tracked by Wall St. Rank hold AURA as of Q2 2026.

  • Adage Capital Partners held 4,640,000 shares of Aura Biosciences worth $32.9M as of Q2 2026.
  • Adage Capital Partners sold 241,125 Aura Biosciences shares in Q2 2026, an estimated $1.73M.
  • Aura Biosciences made up 0.05% of Adage Capital Partners's portfolio in Q2 2026, its #368 holding.
  • Adage Capital Partners first reported a position in Aura Biosciences in Q4 2021 and has held it in 19 quarters since.
  • Adage Capital Partners's Aura Biosciences position peaked at $43.5M in Q3 2024.
  • 147 funds tracked by Wall St. Rank held Aura Biosciences as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.